Paperpal Prime Logo

ACS Medicinal Chemistry Letters : Impact Factor & More

eISSN: 1948-5875pISSN: 1948-5875

Aims and Scope of ACS Medicinal Chemistry Letters

ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. Founded in 2009, this online journal is published monthly by the American Chemical Society. The Editor-in-Chief is Dennis C. Liotta (Emory University, Atlanta, Georgia, USA). Less

Key Metrics

CiteScore
6.6
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
SJR
Q2Biochemistry
SNIP
0.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on ACS Medicinal Chemistry Letters

ACS Medicinal Chemistry Letters Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher AMER CHEMICAL SOC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2010
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in ACS Medicinal Chemistry Letters ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in ACS Medicinal Chemistry Letters

Discovery of 2H-Pyrrolo[3,4‑c]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated In Vivo Efficacy.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Design and Synthesis of Phosphonoproline-Proline Bioisosteric Mimetics of Proline Dimers: Pseudopeptide Constructs as Potential Inhibitors of the Zn-Metalloprotease PPEP-1 Associated with <i>Clostridioides difficile</i>
  • 11 Jun 2026
  • ACS Medicinal Chemistry Letters
Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Novel Compounds as TREM2 Modulators for Treating Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Nasu-Hakola Disease.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Discovery of 2H-Pyrrolo[3,4‑c]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated In Vivo Efficacy.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Design and Synthesis of Phosphonoproline-Proline Bioisosteric Mimetics of Proline Dimers: Pseudopeptide Constructs as Potential Inhibitors of the Zn-Metalloprotease PPEP-1 Associated with <i>Clostridioides difficile</i>
  • 11 Jun 2026
  • ACS Medicinal Chemistry Letters
Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.
  • 11 Jun 2026
  • ACS medicinal chemistry letters
Novel Compounds as TREM2 Modulators for Treating Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Nasu-Hakola Disease.
  • 11 Jun 2026
  • ACS medicinal chemistry letters

FAQs on ACS Medicinal Chemistry Letters